* Q4 loss/shr $0.07 vs est loss/shr $0.13
* Q4 rev jumps 52 pct
* Shares up as much as 5 pct in after-mkt trade
March 4 (Reuters) - Depomed Inc posted a narrower-than-expected quarterly loss, helped by a nearly four-fold increase in license revenue, sending its shares up as much as 5 percent in after-market trade.
For the fourth quarter, the specialty pharmaceutical company reported a net loss of $3.6 million, or 7 cents a share, compared with a loss of $11.2 million, or 22 cents a share, a year earlier.
Analysts on average had expected a loss of 13 cents a share, excluding items, on revenue of $13.3 million, according to Thomson Reuters I/B/E/S.
Total revenue rose 52 percent to $13.2 million.
License revenue rose to $3.2 million in the quarter from 834,000 in the year-ago period.
Shares of the company rose 5 percent to $3 in after-market trade. They closed at $2.87 Thursday on Nasdaq.
(Reporting by Shailesh Kuber in Bangalore; Editing by Maju Samuel) Keywords: DEPOMED/ (shailesh.kuber@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging: shailesh.kuber.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Q4 rev jumps 52 pct
* Shares up as much as 5 pct in after-mkt trade
March 4 (Reuters) - Depomed Inc posted a narrower-than-expected quarterly loss, helped by a nearly four-fold increase in license revenue, sending its shares up as much as 5 percent in after-market trade.
For the fourth quarter, the specialty pharmaceutical company reported a net loss of $3.6 million, or 7 cents a share, compared with a loss of $11.2 million, or 22 cents a share, a year earlier.
Analysts on average had expected a loss of 13 cents a share, excluding items, on revenue of $13.3 million, according to Thomson Reuters I/B/E/S.
Total revenue rose 52 percent to $13.2 million.
License revenue rose to $3.2 million in the quarter from 834,000 in the year-ago period.
Shares of the company rose 5 percent to $3 in after-market trade. They closed at $2.87 Thursday on Nasdaq.
(Reporting by Shailesh Kuber in Bangalore; Editing by Maju Samuel) Keywords: DEPOMED/ (shailesh.kuber@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging: shailesh.kuber.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.